Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683710 | 0.87 | HTR2A (0.73) | HTR2AADORA2BKMT2A | |
| SCHEMBL684015 | 0.86 | LMNA (0.49) | HTR2ADGKADGKZADORA2BKMT2A | |
| SCHEMBL684071 | 0.80 | HTR2A (0.81) | HTR2AADORA2BKMT2A | |
| SCHEMBL683669 | 0.78 | MAPK1 (0.45) | HTR2AADORA2BMAPK1NPSR1GLA | |
| SCHEMBL683711 | 0.75 | HTR2A (0.58) | HTR2AADORA2BKMT2AMAPK1GLA | |
| SCHEMBL684023 | 0.73 | HTR2A (0.58) | HTR2AADORA2BKMT2AMAPK1GLA | |
| SCHEMBL683646 | 0.73 | HTR2A (0.52) | HTR2AADORA2BKMT2AMAPK1NPSR1 | |
| SCHEMBL682832 | 0.73 | MAPT (0.49) | HTR2AADORA2BKMT2AMAPK1GLA | |
| SCHEMBL683671 | 0.72 | HTR2A (0.54) | HTR2AADORA2BKMT2AMAPK1GLA | |
| SCHEMBL683707 | 0.71 | ADORA2B (0.45) | HTR2AADORA2BKMT2AMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | HTR2A 1201/4885DGKA 1738/4885DGKZ 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.